1,108 reports of this reaction
5.4% of all NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, manufactured by Nalpropion Pharmaceuticals LLC. There are 1,108 FDA adverse event reports linking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE to HEADACHE. This represents approximately 5.4% of all 20,475 adverse event reports for this drug.
Patients taking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,108 FDA reports for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 5.4% of all adverse event reports for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience headache while taking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.